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Abstract 
Background 
Following surgery for non-metastatic renal cell carcinoma (RCC) with tumor thrombus, 
the risk of recurrence is significant but variable among individual patients.  The purpose 
of this study is to develop and validate a predictive nomogram for individual estimation 
of recurrence risk following surgery for RCC with venous tumor thrombus. 
 
 
Methods 
Comprehensive data was collected for non-metastatic RCC patients with thrombus 
treated at 5 institutions from 2000-2013. Independent predictors of RCC recurrence 
from a competing risks analysis were developed into a nomogram. Predictive accuracy 
was compared between development/ validation cohorts and between the nomogram, 
the UCLA Integrated Staging System (UISS), SSIGN and Sorbellini models. 
 
 
Results  
A total of 636 patients were analyzed (development cohort n=465, validation cohort 
n=171).  Independent predictors (tumor diameter, BMI, Preoperative hemoglobin < 
lower limit of normal, thrombus level, perinephric fat invasion, and non-clear cell 
histology) were developed into a nomogram. Estimated 5-year recurrence free survival 
(RFS) was 49% overall. The 5 year RFS for patients with 0, 1, 2, >2 risk factors was 
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77%, 53%, 47%, and 20% respectively. Predictive accuracy was similar in development 
and validation cohorts (AUC 0.726 and 0.724). 
 
Predictive accuracy for the thrombus nomogram was higher than the UISS (AUC 0.726 
vs. 0.595, p=0.001), SSIGN (AUC 0.713 vs. 0.612, p =0.04) or the Sorbellini models 
(AUC 0.709 vs. 0.638, p=0.02).   
  
 
Conclusions 
A predictive nomogram for postoperative recurrence in non-metastatic RCC patients 
with venous thrombus is presented.  Improving individual post-operative risk 
assessment may allow better design and analysis of future adjuvant clinical trials. 
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Introduction  
 
Following surgery for non-metastatic renal cell carcinoma (RCC) with tumor 
thrombus approximately 50% of patients have disease recurrence, making these 
patients ideal to study in adjuvant clinical trials.1 Although the overall recurrence risk 
varies significantly, individual risk can be estimated using clinical and pathologic 
variables. Since non-metastatic RCC patients with thrombus represent a relatively 
unique population, risk assessment following surgery may not be similar to other RCC 
patients. In a prior study, risk factors were identified and used to separate patients into 
favorable, intermediate and high risk groups with 22%, 55%, and 79% 5-year 
recurrence free survival following surgery for RCC with thrombus.2 However, a 
nomogram for individual risk assessment has not been previously described for this 
unique population of RCC patients, who are at high risk for recurrence following 
surgery.   
Clinical trials of adjuvant therapy following surgery for RCC have been 
disappointing with the exception of the recent S-TRAC trial.3  One persistent criticism of 
adjuvant clinical trial design is that there is significant heterogeneity of recurrence risk 
among patients enrolled. 4 Assigning accurate baseline risk is critical in when trying to 
evaluate whether patients actually have risk reduction from adjuvant therapies.  In the 
recently published ASSURE and the S-TRAC clinical trials, patients were stratified into 
intermediate or high risk for recurrence based on the well-known and validated UCLA 
Integrated Staging System (UISS). 5 However, this system and others 6, 7 were 
developed to stratify risk among a general population of RCC patients, and it is unclear 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
how well this system performs to further stratify a population of high risk patients, such 
as non-metastatic RCC patients with tumor thrombus. Therefore, the purpose of our 
study was to develop a nomogram to predict individual 5- year recurrence risk following 
surgery in non-metastatic RCC patients with tumor thrombus, to evaluate the predictive 
accuracy in independent populations and to compare the predictive ability of this 
nomogram with the UISS, SSIGN, and Sorbellini models.  
 
Materials and Methods      
 
 Following IRB approval, comprehensive clinical and pathologic data were 
reviewed for consecutive non-metastatic RCC patients with tumor thrombus from 2000-
2013 at 5 institutions.  The development cohort included patients from: the University of 
Wisconsin (UW), the University of Texas Southwestern Medical Center (UTSW), and 
the MD Anderson Cancer Center (MDA), while the validation cohort included patients 
from: Emory University, Indiana University (IU). Preoperative assessment for metastatic 
disease was similar for each institution and included preoperative laboratory evaluation 
in addition to computed tomography (CT) or magnetic resonance imaging (MRI) scans 
of the chest, abdomen, and pelvis.  All patients with radiographic or pathologic evidence 
of distant metastatic or nodal metastases at presentation were excluded from analysis. 
No patients had pre-surgical systemic therapy.  Follow up after surgery generally 
consisted of CT of chest, abdomen, and pelvis every 3-6 months for the first 5 years 
and yearly thereafter.  
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 Clinical and laboratory factors assessed for each patient included the following: 
age, gender, BMI, tumor width and height, albumin levels, neutrophil count, lymphocyte 
count, neutrophil/ lymphocyte ratio, hemoglobin, creatinine, and tumor diameter.  
Surgical and pathologic factors assessed for each patient included: year of surgery, 
grade, stage, thrombus level according to Neves system,8 sarcomatoid features, tumor 
histology, local and systemic symptoms, estimated blood loss, perinephric fat invasion, 
and perioperative blood transfusion.  All pathologic specimens were examined by an 
institutional genitourinary pathologist.  Histological subtypes were categorized according 
to the 2004 World Health Organization classification. 
Statistical Analysis        
 To evaluate the effect of death from other causes, competing risks analysis was 
integrated with univariate and multivariate Cox proportional hazard models for putative 
risk factors for RCC recurrence.9 Significant variables following multivariate competing 
risks analysis were used to construct a predictive nomogram. The predictive accuracy of 
the nomogram was evaluated using receiver operating characteristics (ROC) curves for 
the development and validation cohorts and further evaluated for clinical applicability 
according to decision curve analysis.10 Estimated recurrence-free survival (RFS) rates 
were calculated using the Kaplan-Meier method. A p-value < 0.05 was considered 
statistically significant and SAS 9.4 (SAS Institute, Cary, NC, USA) or R 3.3.1 was used 
for all analyses.  
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Results   
 A total of 636 non-metastatic RCC patients treated with radical nephrectomy and 
tumor thrombectomy were available for analysis.  Table 1 shows patient clinical and 
pathologic characteristics.  Median follow up for the study period was 24.8 months (IQR 
9.2-50.3).  Tumor thrombus level included 342 (53.8%) renal vein, 92 (14.5%) level 1, 
100 (15.7%) level 2, 45 (7.1%) level 3, and 57 (9.0%) level 4.  Recurrent renal cell 
carcinoma was identified in 239 (37.5%) patients during follow-up.  Competing risk 
analysis identified variables associated with disease recurrence in the 465 patients for 
the development cohort (table 2).  Independently predictive variables associated with 
RCC recurrence included: tumor diameter in cm (HR 1.05, 95% CI 1.004-1.09; p=0.03), 
BMI (HR 0.97, 95% CI 0.95-0.997; p=0.03), Preoperative hemoglobin < lower limit of 
normal (HR 1.59, 95% CI 1.11-2.27; p=0.01), thrombus level (HR 2.4, 95% CI 1.3-4.3; 
p=0.005), perinephric fat invasion (HR 1.5, 95% CI 1.05-2.02; p=0.03), and non-clear 
cell histology (HR 1.8, 95% CI 1.06-3.0; p=0.03).  Estimated 5-year RFS was 49% 
overall. When independent predictors were considered unweighted, the 5 year RFS for 
patients with 0, 1, 2, >2 risk factors was 77%, 53%, 47%, and 20% respectively. (Figure 
1 supplemental)    
 Risk factors for recurrence were developed into a predictive nomogram for 
recurrence of RCC following nephrectomy and tumor thrombectomy (figure 1).  ROC 
curves were constructed to evaluate the predictive accuracy of the model.  The area 
under the curve (AUC) for the nomogram in the development cohort (n=465; UW, 
UTSW, MDA) and validation cohort (n=171; Emory, IU) were 0.726 and 0.724 
respectively (Figure 2). Decision curve analysis was performed to determine the 
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potential clinical benefit of the nomogram to predict RCC recurrence for differing 
thresholds.  Decision curves for net benefit are displayed in Figure 2 supplemental.  The 
decision curve analysis demonstrates predictive ability for the nomogram for risk 
thresholds between 20-80%. Sites of recurrence are shown in supplemental figure 3. 
 Patients were classified according to UISS system as previously described,5 and 
figure 3a shows Kaplan Meier estimated survival according to UISS intermediate or high 
risk groups (p=0.001).  Using only patients from the UISS high risk cohort, risk factors 
from the thrombus nomogram were able to further predict recurrence risk, with 5 year 
RFS for 0, 1, 2, >2 risk factors of 84%, 48%, 44%, and 17% respectively (figure 3b). 
Similarly, for intermediate risk UISS patients, the number of risk factors from the 
thrombus nomogram were able to significantly predict recurrence risk, with 5 year RFS 
for 0, 1, 2, >2 risk factors of 75%, 57%, 53%, and 30% respectively (figure 3c). ROC 
curves were constructed to evaluate the predictive accuracy of the thrombus model vs. 
the UISS model (figure 4a), the SSIGN model (figure 4b), and the Sorbellini model 
(figure 4c).  Predictive accuracy for the thrombus nomogram was higher than the UISS 
model (AUC 0.726 vs. 0.595, p=0.001), SSIGN model (AUC 0.713 vs. 0.612, p =0.04) 
or the Sorbellini model (AUC 0.709 vs. 0.638, p=0.02).   
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Discussion 
 
 Non-metastatic RCC patients with venous tumor thrombus are ideal candidates 
for studying in adjuvant clinical trials because approximately 50% of patients are non-
metastatic at presentation and approximately 50% of patients recur following surgery.  
However, there is significant variability with respect to individual recurrence risk. Herein, 
we present a predictive nomogram for risk of 5-year recurrence that was developed and 
validated using contemporary independent populations of patients treated at five 
centers.  Importantly, the predictive accuracy of the nomogram was greater than the 
UISS model, which is used to stratify RCC patients in recently reported adjuvant therapy 
clinical trials.3, 11 The low predictive accuracy of the original UISS model was not 
surprising as it included only 13.9% high risk patients.5 Similarly, the SSIGN and 
Sorbellini models were developed with general RCC patients and these models have 
low predictive accuracy when compared to the nomogram.  Importantly, the thrombus 
nomogram also demonstrated the ability to further stratify patients who were already 
identified as high risk by the UISS model. Improved ability to identify individual 
recurrence risk in non-metastatic RCC patients with thrombus may allow for better 
postoperative patient counseling and facilitates ideal patient selection and analysis for 
future adjuvant therapy clinical trials. 
 
When developing risk assessment tools that will be applied widely, multicenter 
data have advantages because it minimizes potential institutional biases. The use of 
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contemporary data is also helpful to avoid inaccuracies associated with comparing 
patients treated over different decades during which imaging techniques, pathologic 
definitions, and surveillance regimens evolved significantly.12-14  However, because 
RCC with thrombus is relatively rare, many prior studies include patients treated at a 
single center of excellence over several decades, include both metastatic and non-
metastatic patients, and use survival endpoints to stratify individual risk.15 However, 
recurrence following surgery is a more stable and clinically useful endpoint since 
survival for metastatic RCC (mRCC) has changed significantly during the last decade. 
11, 16
 Furthermore, risks for non-metastatic patients should be evaluated separately from 
mRCC patients since the presence of metastatic disease itself, is the critical 
determinant of survival in these patients. In the current series, data from non-metastatic 
consecutive patients treated surgically at 5 independent centers since 2000 were used 
to create a risk prediction model with a similar predictive accuracy in the development 
and validation cohorts, which outperform the current risk models for general RCC. In 
2016, the S-TRAC clinical trial showed improvement in disease free survival for patients 
receiving sunitinib vs. placebo.3 If future studies demonstrate improved survival, many 
non-metastatic RCC patients with thrombus would be excellent candidates to begin 
adjuvant therapy following surgery.  
 
 It is estimated that 10% of all RCC tumors will have thrombus extension into the 
venous system, 17, 18 and these patients are ideal for clinical trials of adjuvant therapy 
because of their high risk for recurrence.  Improving the ability to identify the highest risk 
RCC patients will facilitate better clinical trial design and more accurate analysis when 
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investigating future adjuvant therapies. Decreasing heterogeneity within the trial 
population while targeting the highest risk patients may also allow for easier 
identification of potential benefits using fewer patients. To date, adjuvant clinical trials 
have used risk stratification tools that were developed for the general RCC population, 
which is more appropriate to separate and exclude low risk patients since these models 
were developed largely (86%) from low and intermediate risk patients,5 reflecting the 
risk for a balanced population of RCC patients overall.19 However, since adjuvant 
clinical trials primarily seek to enroll high risk patients, it is critical to use predictive 
models that are developed from high-risk cohorts of patients which enable stratification 
among a primarily high risk population. Non-metastatic RCC patients with thrombus 
have high but variable risk of recurrence and may benefit improved baseline risk 
assessment when considering enrollment in future adjuvant therapy clinical trials.   
 
  Limitations to this study include the retrospective approach and subsequent 
potential for biases.  There were likely subtle differences in diagnostic and treatment 
approaches at different centers that could bias results.  However, this multi-institutional 
approach may also allow findings to be more applicable at other centers. To evaluate 
associations with recurrence risk and putative risk factors while adjusting for risk in 
patients who died of other causes following surgery, a competing risks analysis was 
used. The independent predictors in this study are similar to prior study which did not 
use a competing risk model and also included tumor grade as a risk factor.2 Tumor 
grade was not included in the final nomogram, as there was no increase in predictive 
accuracy when grade was considered (AUC=0.724 vs. 0.726, data not shown). Data 
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from 3 independent centers were included in the development cohort, and data from 2 
additional centers were used for validation. The variables that have been evaluated in 
this study are commonly measured and should be able to be applied widely to measure 
risk. Common pathology traits were reviewed but there was no centralized pathology 
review.  However, this approach more closely represents current practice.  Finally, the 
predictive accuracy of the nomogram measured by ROC curves was fair, similar in the 
development and test cohort, and superior to the UISS, SSIGN and Sorbellini models.   
 
Conclusion  
 Using multi-institutional contemporary data, we developed a predictive 
nomogram with external validation for 5-year recurrence risk following surgery for non-
metastatic RCC with thrombus.  Improving risk assessment following surgery allows for 
improved postoperative counselling and better design and analysis of future adjuvant 
clinical trials in high risk RCC patients.    
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Figure legends: 
 
 
Figure 1. Predictive nomogram for recurrence following surgery in non-metastatic RCC 
patients with thrombus  
 
Figure 2. ROC curves evaluating predictive accuracy in development cohort (n=465) vs. 
validation cohort (n=171) for 5-year recurrence following surgery in non-metastatic RCC 
patients with thrombus  
 
Figure 3a. Kaplan Meier analysis recurrence following nephrectomy with thrombectomy 
in intermediate or high risk groups according to UISS 
 
Figure 3b. Kaplan Meier analysis recurrence following nephrectomy with thrombectomy 
using risk factors from thrombus nomogram in UISS high risk group only  
 
Figure 3c. Kaplan Meier analysis recurrence following nephrectomy with thrombectomy 
using risk factors from thrombus nomogram in UISS intermediate risk group only  
 
Figure 4a. ROC curves evaluating predictive accuracy in UISS model (AUC 0.595) vs. 
thrombus nomogram (AUC 0.726) for 5-year recurrence following surgery in non-
metastatic RCC patients with thrombus p=0.001  
 
Figure 4b. ROC curves evaluating predictive accuracy in SSIGN model (AUC 0.612) vs. 
thrombus nomogram (AUC 0.713) for 5-year recurrence following surgery in non-
metastatic RCC patients with thrombus p =0.04 
 
Figure 4c. ROC curves evaluating predictive accuracy in Sorbellini model (AUC 0.638) 
vs. thrombus nomogram (AUC 0.709) for 5-year recurrence following surgery in non-
metastatic RCC patients with thrombus p=0.02 
 
Figure 1 supplemental. Kaplan Meier analysis according to 6 predictive factors for 
recurrence following nephrectomy with thrombectomy in 636 non-metastatic RCC 
patients 
 
Figure 2 supplemental. Decision curve analysis demonstrates that for threshold 
probability between 20 – 80%, the nomogram has a positive net clinical benefit for 
predicting RCC recurrence following surgery. 
 
Figure 3 supplemental. Sites of recurrence for non-metastatic RCC patients with 
thrombus following surgery at 5 institutions 
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Table 1: Patient and disease characteristics 
 
Characteristic N=636(%) 
Median age in years (IQR) 63.4(55.0-71.4) 
Median body mass index (IQR) 29.3(26-34.4) 
Gender                                                              Male 423(66.5) 
       Female 213(33.5) 
Local symptoms                                                 No 292(47.8) 
       Yes 319(52.2) 
       Missing data 25 
Systemic symptoms                                          No 500(79.6) 
       Yes 128(20.4) 
       Missing data 8 
ABO blood type                                                     A 206(37.2) 
       AB 23(4.2) 
       B 63(11.4) 
       O 262(47.3) 
       Missing data 82 
Smoker                                                                 No 297(51.2) 
       Yes 283(48.8) 
       Missing data 56 
Tumor thrombus                            Renal vein only 342(53.8) 
       IVC <2cm 92(14.5) 
       IVC >2cm 100(15.7) 
       IVC below diaphragm 45(7.1) 
       IVC above diaphragm 57(9.0) 
Surgery year                                2000-2007 290(45.6) 
       2008-2013 346(54.4) 
Median maximum tumor width in cm (IQR) 9(6.5-12) 
Perinephric fat invasion                                     No 301(47.3) 
       Yes 335(52.7) 
2009 AJCC Pathological  T stage                     T3a 302(47.5) 
     T3b 264(41.5) 
       T3c 53(8.3) 
       T4 17(2.7) 
Nuclear grade                                                     1+2 136(21.4) 
       3 351(55.2) 
       4 149(23.4) 
Histologic subtype                          Clear cell RCC 591(92.9) 
       Non-clear cell RCC 45(7.1) 
Sarcomatoid features present?                         No 591(92.9) 
       Yes 45(7.1) 
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Table 2. Univariate and Multivariate Competing Risks Analysis for evaluation of 
association of RCC recurrence and putative risk factors  
 
 Univariate Multivariate 
Characteristic Hazard Ratio [95% CI] p-value Hazard Ratio [95% CI] p-value 
Age 1.0 [0.99-1.01] 0.72   
Gender     
       Male ref    
       Female 1.11 [0.82-1.49] 0.49   
Body Mass Index 0.97[0.95-0.998] 0.03 0.97[0.95-0.997] 0.03 
Local symptoms     
       No ref    
       Yes 0.99[0.74-1.32] 0.95   
Systemic symptoms     
       No ref  ref  
       Yes 1.78[1.31-2.41] 0.0002 1.27[0.90-1.79] 0.18 
Blood type     
       O ref    
       A 1.09[0.79-1.51] 0.57   
       AB 0.48[0.18-1.33] 0.16   
       B 0.88[0.51-1.51] 0.63   
Smoking     
       No ref    
       Yes 0.86[0.64-1.14] 0.29   
Thrombus height     
       Renal vein only ref  ref  
       IVC <2cm 0.94[0.59-1.49] 0.81 0.83[0.51-1.35] 0.45 
       IVC >2cm 1.24[0.84-1.83] 0.27 0.90[0.58-1.39] 0.64 
       IVC below diaphragm 2.96[1.74-5.05] <0.0001 2.36[1.29-4.30] 0.005 
       IVC above  diaphragm   1.91[1.17-3.10] 0.009 1.18[0.68-2.03] 0.55 
Year of surgery     
       2000-2007 ref    
       2008-2013 1.07[0.79-1.45] 0.64   
Preoperative labs     
       Albumin (per g/dl) 0.91 [0.73-1.15] 0.44   
       Hemoglobin <LLN 2.12[1.57-2.88] <0.0001 1.59[1.11-2.27] 0.01 
       Neutrophil (per unit) 1.02 [0.99-1.04] 0.17   
       Lymphocyte (per unit) 0.97 [0.87-1.09] 0.66   
       Neutrophil: lymphocyte ratio 1.04 [0.99-1.08] 0.08   
Histologic subtype     
       Clear cell ref  ref  
       Non-clear cell 2.28[1.44-3.61] 0.0004 1.78[1.06-2.99] 0.03 
Maximum tumor width (per cm) 1.09 [1.05-1.12] <0.0001 1.05[1.004-1.09] 0.03 
Pathological stage     
       T3a ref    
       T3b 1.27[0.93-1.74] 0.12   
       T3c 2.24[1.36-3.69] 0.001   
       T4 1.75[0.85-3.61] 0.12   
Nuclear grade     
       1+2 ref  ref  
       3 1.53[0.97-2.43] 0.07 1.04[0.63-1.72] 0.87 
       4 2.57[1.58-4.19] 0.0001 1.56[0.88-2.76] 0.13 
Perinephric fat invasion 1.77[1.33-2.37] <0.0001 1.46[1.05-2.02] 0.03 
Sarcomatoid features 1.94 [1.22-3.09] 0.01 1.09[0.61-1.94] 0.77 
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KEY OF ABBREVIATIONS 
 
renal cell carcinoma (RCC), Inferior Vena Cava (IVC), recurrence-free survival (RFS), UCLA 
Integrated Staging System (UISS), Stage, Size, Grade and Necrosis (SSIGN), body mass index 
(BMI), inter quartile range (IQR), reference (ref), hazard ratio (HR), confidence interval (CI), 
year (yr), upper limit of normal (ULN), lower limit of normal (LLN) 
 
